Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
20 08 2020
Historique:
received: 26 11 2019
accepted: 12 02 2020
pubmed: 20 2 2020
medline: 22 6 2021
entrez: 20 2 2020
Statut: epublish

Résumé

This study summarizes drug resistance analyses in 4 recent phase 2b trials of the respiratory syncytial virus (RSV) fusion inhibitor presatovir in naturally infected adults. Adult hematopoietic cell transplant (HCT) recipients, lung transplant recipients, or hospitalized patients with naturally acquired, laboratory-confirmed RSV infection were enrolled in 4 randomized, double-blind, placebo-controlled studies with study-specific presatovir dosing. Full-length RSV

Identifiants

pubmed: 32071058
pii: AAC.02312-19
doi: 10.1128/AAC.02312-19
pmc: PMC7449164
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

J Virol. 2010 Aug;84(15):7500-12
pubmed: 20504933
Pediatr Infect Dis J. 2010 Oct;29(10):898-904
pubmed: 20442686
Clin Infect Dis. 2007 Oct 15;45(8):1019-24
pubmed: 17879919
Clin Infect Dis. 2006 Dec 15;43(12):1555-61
pubmed: 17109288
Antimicrob Agents Chemother. 2004 Feb;48(2):413-22
pubmed: 14742189
J Infect Dis. 2013 May 1;207(9):1424-32
pubmed: 23382572
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):E3441-9
pubmed: 25092342
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13
pubmed: 19966279
Pediatrics. 2014 Aug;134(2):415-20
pubmed: 25070315
Nat Chem Biol. 2016 Feb;12(2):87-93
pubmed: 26641933
Clin Infect Dis. 1996 May;22(5):778-82
pubmed: 8722930
J Infect Dis. 2020 Jan 14;221(3):367-371
pubmed: 31541547
Arch Pediatr Adolesc Med. 1996 Sep;150(9):942-7
pubmed: 8790125
Influenza Other Respir Viruses. 2018 Mar;12(2):267-278
pubmed: 29265727
PLoS One. 2017 Apr 17;12(4):e0175792
pubmed: 28414749
J Clin Pharmacol. 2018 Jun;58(6):771-780
pubmed: 29412463
Emerg Infect Dis. 2019 Nov;25(11):2108-2111
pubmed: 31436527
J Infect Dis. 2020 Jan 1;221(1):63-70
pubmed: 31419295
Clin Infect Dis. 2019 Dec 03;:
pubmed: 31915807
N Engl J Med. 2014 Aug 21;371(8):711-22
pubmed: 25140957
Virology. 2003 Jul 5;311(2):275-88
pubmed: 12842618
Am J Respir Crit Care Med. 2004 Jul 15;170(2):181-7
pubmed: 15130908
Clin Infect Dis. 2010 May 1;50(9):1252-5
pubmed: 20345239
Clin Infect Dis. 2019 Dec 03;:
pubmed: 31793991
N Engl J Med. 2005 Apr 28;352(17):1749-59
pubmed: 15858184
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228
J Infect Dis. 2020 Jan 23;:
pubmed: 31971597

Auteurs

Danielle P Porter (DP)

Gilead Sciences, Inc., Foster City, California, USA Danielle.Porter@gilead.com.

Ying Guo (Y)

Gilead Sciences, Inc., Foster City, California, USA.

Jason Perry (J)

Gilead Sciences, Inc., Foster City, California, USA.

David L Gossage (DL)

Gilead Sciences, Inc., Foster City, California, USA.

Timothy R Watkins (TR)

Gilead Sciences, Inc., Foster City, California, USA.

Jason W Chien (JW)

Gilead Sciences, Inc., Foster City, California, USA.

Robert Jordan (R)

Gilead Sciences, Inc., Foster City, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH